

(<http://aphanet.org>)

[Home](#) > Not associated with increased cancer risk

Generic Name:

Angiotensin receptor blockers (ARBs)

Trade Name:

Various trade names

Company:

Various manufacturer

Notes:

The results of [FDA](#)'s comprehensive trial-level meta-analysis of data from 31 trials involving approximately 156,000 patients showed that patients taking an ARB did not have an increased risk of cancer, compared with those on non-ARB therapy. FDA found no evidence of an association between ARBs and cancer-related death, breast cancer, lung cancer, or prostate cancer. In July 2010, FDA stated that it would conduct this review after a published meta-analysis of 5 randomized clinical trials reported a small but statistically significant increase in the risk of cancer in patients taking ARBs.

Medication Monitor Categories:

[Alerts and Recalls](#)

Source URL: <http://aphanet.org/alerts-and-recalls/not-associated-increased-cancer-risk>